Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Account Payables (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Change in Account Payables for 7 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables fell 60.12% to $3.0 million in Q4 2025 year-over-year; TTM through Nov 2025 was -$630000.0, a 112.09% decrease, with the full-year FY2025 number at -$630000.0, down 112.09% from a year prior.
  • Change in Account Payables was $3.0 million for Q4 2025 at Nurix Therapeutics, up from $2.2 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $7.6 million in Q4 2024 to a low of -$3.2 million in Q1 2025.
  • A 5-year average of $393350.0 and a median of $148500.0 in 2022 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: surged 617.24% in 2023, then tumbled 332.5% in 2024.
  • Nurix Therapeutics' Change in Account Payables stood at $862000.0 in 2021, then crashed by 204.29% to -$899000.0 in 2022, then soared by 617.24% to $4.6 million in 2023, then surged by 63.12% to $7.6 million in 2024, then tumbled by 60.12% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Change in Account Payables are $3.0 million (Q4 2025), $2.2 million (Q3 2025), and -$2.7 million (Q2 2025).